Drugs / Polaprezinc
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05549778 | Jan 2021 → Jan 2023 | castration-resistant prostate carcinoma | Jiangnan University | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT04430998 | Jun 2020 | periodontal disorder | University of Milan | Unknown | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT06664008 | Nov 2024 → Mar 2025 overdue | gastroesophageal reflux disease | Ain Shams University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT03467438 | Nov 2018 → Apr 2020 | gastroesophageal reflux disease | Fondazione IRCCS Policlinico San Matteo di Pavia | Unknown | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT02243618 Comparator | Jan 2015 → Apr 2016 | gastric adenoma, gastric carcinoma | Yonsei University | Completed | No outcome recorded |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Polaprezinc | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05549778 ↗ |
| Known as | Hepilor | “Zinc L-carnosine (brand name in Italy: Hepilor®) is a chelate compound of zinc and L-carnosine, with a long history of more than 20 years of clinical use in Japan that has...” NCT03467438 ↗ |
| Known as | PepZin GI | “Zinc-L-carnosine (ZnC), also called polaprezinc (otherwise known as PepZin GI™), is a chelated compound that contains L-carnosine and zinc.” NCT05549778 ↗ |
| Known as | Zinc | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06664008 ↗ |
| Known as | Zinc L-carnosine | “Zinc L-carnosine (brand name in Italy: Hepilor®) is a chelate compound of zinc and L-carnosine, with a long history of more than 20 years of clinical use in Japan that has...” NCT03467438 ↗4“Zinc, specifically Zinc L-carnosine, exhibits antioxidant, cytokine modulation, and membrane-stabilizing properties, acting as a mucosal cytoprotective and anti-inflammatory agent” NCT06664008 ↗ “Zinc-L-carnosine (ZnC), also called polaprezinc (otherwise known as PepZin GI™), is a chelated compound that contains L-carnosine and zinc.” NCT05549778 ↗ |
| Known as | ZnC | “Zinc-L-carnosine (ZnC), also called polaprezinc (otherwise known as PepZin GI™), is a chelated compound that contains L-carnosine and zinc.” NCT05549778 ↗ |
| Action | Inhibit | “repurposed polaprezinc (POL) as its inhibitor” NCT05549778 ↗ |
| Modality | Other / unclassified | “is a chelate compound of zinc and L-carnosine” NCT03467438 ↗ |
| Route | Oral | “liquid oral formulation” NCT03467438 ↗ |
| Target | PRDX5 | “We have identified PRDX5 as a therapeutic target and repurposed polaprezinc (POL) as its inhibitor for the treatment of CRPC.” NCT05549778 ↗ |